nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—EGFR—Docetaxel—skin cancer	0.218	0.351	CbGbCtD
Lapatinib—CYP2C8—Vismodegib—skin cancer	0.0708	0.114	CbGbCtD
Lapatinib—CYP2C19—Vismodegib—skin cancer	0.0594	0.0955	CbGbCtD
Lapatinib—ABCB1—Vismodegib—skin cancer	0.0479	0.0771	CbGbCtD
Lapatinib—CYP3A4—Temozolomide—skin cancer	0.0414	0.0666	CbGbCtD
Lapatinib—CYP3A4—Imiquimod—skin cancer	0.0414	0.0666	CbGbCtD
Lapatinib—CYP3A4—Vismodegib—skin cancer	0.0287	0.0462	CbGbCtD
Lapatinib—ABCB1—Dactinomycin—skin cancer	0.0252	0.0405	CbGbCtD
Lapatinib—CYP2C8—Fluorouracil—skin cancer	0.0251	0.0404	CbGbCtD
Lapatinib—CYP3A4—Vemurafenib—skin cancer	0.0227	0.0365	CbGbCtD
Lapatinib—CYP3A5—Docetaxel—skin cancer	0.02	0.0321	CbGbCtD
Lapatinib—ABCB1—Docetaxel—skin cancer	0.013	0.0209	CbGbCtD
Lapatinib—CYP3A4—Docetaxel—skin cancer	0.00779	0.0125	CbGbCtD
Lapatinib—TAP1—nipple—skin cancer	0.00515	0.0776	CbGeAlD
Lapatinib—PIK3C2B—nipple—skin cancer	0.00483	0.0728	CbGeAlD
Lapatinib—ERBB2—nipple—skin cancer	0.00376	0.0566	CbGeAlD
Lapatinib—ERBB2—neck—skin cancer	0.00372	0.056	CbGeAlD
Lapatinib—PI4KB—nipple—skin cancer	0.00352	0.0531	CbGeAlD
Lapatinib—TAP1—mammalian vulva—skin cancer	0.00301	0.0453	CbGeAlD
Lapatinib—PIK3C2B—mammalian vulva—skin cancer	0.00282	0.0425	CbGeAlD
Lapatinib—ERBB2—connective tissue—skin cancer	0.00267	0.0402	CbGeAlD
Lapatinib—ERBB2—epithelium—skin cancer	0.00253	0.0381	CbGeAlD
Lapatinib—ERBB4—epithelium—skin cancer	0.00253	0.0381	CbGeAlD
Lapatinib—PIK3C2B—female reproductive system—skin cancer	0.00242	0.0364	CbGeAlD
Lapatinib—ERBB2—skin of body—skin cancer	0.00241	0.0363	CbGeAlD
Lapatinib—PI4KB—mammalian vulva—skin cancer	0.00206	0.031	CbGeAlD
Lapatinib—PIK3C2B—head—skin cancer	0.00202	0.0304	CbGeAlD
Lapatinib—ERBB2—lymphoid tissue—skin cancer	0.00195	0.0294	CbGeAlD
Lapatinib—ERBB4—female reproductive system—skin cancer	0.00188	0.0283	CbGeAlD
Lapatinib—ERBB2—female reproductive system—skin cancer	0.00188	0.0283	CbGeAlD
Lapatinib—EGFR—mammalian vulva—skin cancer	0.00186	0.028	CbGeAlD
Lapatinib—PI4KB—female reproductive system—skin cancer	0.00176	0.0265	CbGeAlD
Lapatinib—ERBB2—head—skin cancer	0.00157	0.0237	CbGeAlD
Lapatinib—ERBB4—head—skin cancer	0.00157	0.0237	CbGeAlD
Lapatinib—TAP1—lymph node—skin cancer	0.00151	0.0227	CbGeAlD
Lapatinib—PI4KB—head—skin cancer	0.00147	0.0222	CbGeAlD
Lapatinib—PIK3C2B—lymph node—skin cancer	0.00141	0.0213	CbGeAlD
Lapatinib—ERBB2—lymph node—skin cancer	0.0011	0.0166	CbGeAlD
Lapatinib—PI4KB—lymph node—skin cancer	0.00103	0.0155	CbGeAlD
Lapatinib—EGFR—lymph node—skin cancer	0.000932	0.014	CbGeAlD
Lapatinib—Angiopathy—Vemurafenib—skin cancer	0.000859	0.00461	CcSEcCtD
Lapatinib—Mediastinal disorder—Vemurafenib—skin cancer	0.000853	0.00458	CcSEcCtD
Lapatinib—Hepatobiliary disease—Imiquimod—skin cancer	0.000851	0.00457	CcSEcCtD
Lapatinib—Alopecia—Vemurafenib—skin cancer	0.000837	0.00449	CcSEcCtD
Lapatinib—Hepatotoxicity—Docetaxel—skin cancer	0.00083	0.00446	CcSEcCtD
Lapatinib—Malnutrition—Vemurafenib—skin cancer	0.000824	0.00443	CcSEcCtD
Lapatinib—Back pain—Vemurafenib—skin cancer	0.000797	0.00428	CcSEcCtD
Lapatinib—Connective tissue disorder—Imiquimod—skin cancer	0.000794	0.00426	CcSEcCtD
Lapatinib—Asthenia—Vismodegib—skin cancer	0.000781	0.00419	CcSEcCtD
Lapatinib—Pruritus—Vismodegib—skin cancer	0.00077	0.00414	CcSEcCtD
Lapatinib—Hot flush—Temozolomide—skin cancer	0.000748	0.00401	CcSEcCtD
Lapatinib—Diarrhoea—Vismodegib—skin cancer	0.000745	0.004	CcSEcCtD
Lapatinib—Menopausal symptoms—Temozolomide—skin cancer	0.000741	0.00398	CcSEcCtD
Lapatinib—Angiopathy—Imiquimod—skin cancer	0.000733	0.00393	CcSEcCtD
Lapatinib—Immune system disorder—Imiquimod—skin cancer	0.000729	0.00392	CcSEcCtD
Lapatinib—Mediastinal disorder—Imiquimod—skin cancer	0.000728	0.00391	CcSEcCtD
Lapatinib—Cough—Vemurafenib—skin cancer	0.000719	0.00386	CcSEcCtD
Lapatinib—Alopecia—Imiquimod—skin cancer	0.000714	0.00383	CcSEcCtD
Lapatinib—Mental disorder—Imiquimod—skin cancer	0.000707	0.0038	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Docetaxel—skin cancer	0.000705	0.00378	CcSEcCtD
Lapatinib—Malnutrition—Imiquimod—skin cancer	0.000703	0.00377	CcSEcCtD
Lapatinib—Arthralgia—Vemurafenib—skin cancer	0.000702	0.00377	CcSEcCtD
Lapatinib—Myalgia—Vemurafenib—skin cancer	0.000702	0.00377	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000697	0.00374	CcSEcCtD
Lapatinib—Vomiting—Vismodegib—skin cancer	0.000692	0.00372	CcSEcCtD
Lapatinib—Rash—Vismodegib—skin cancer	0.000687	0.00369	CcSEcCtD
Lapatinib—Dermatitis—Vismodegib—skin cancer	0.000686	0.00368	CcSEcCtD
Lapatinib—Back pain—Imiquimod—skin cancer	0.00068	0.00365	CcSEcCtD
Lapatinib—Blood bilirubin increased—Docetaxel—skin cancer	0.000678	0.00364	CcSEcCtD
Lapatinib—ABCB1—blood vessel—skin cancer	0.000677	0.0102	CbGeAlD
Lapatinib—Anaphylactic shock—Vemurafenib—skin cancer	0.000673	0.00361	CcSEcCtD
Lapatinib—Infection—Vemurafenib—skin cancer	0.000668	0.00359	CcSEcCtD
Lapatinib—Cardiac failure—Fluorouracil—skin cancer	0.00066	0.00355	CcSEcCtD
Lapatinib—Nervous system disorder—Vemurafenib—skin cancer	0.00066	0.00354	CcSEcCtD
Lapatinib—Skin disorder—Vemurafenib—skin cancer	0.000653	0.00351	CcSEcCtD
Lapatinib—Dehydration—Temozolomide—skin cancer	0.000651	0.00349	CcSEcCtD
Lapatinib—Nausea—Vismodegib—skin cancer	0.000647	0.00347	CcSEcCtD
Lapatinib—Pneumonia—Bleomycin—skin cancer	0.000643	0.00345	CcSEcCtD
Lapatinib—Dry skin—Temozolomide—skin cancer	0.000641	0.00344	CcSEcCtD
Lapatinib—Neutropenia—Dactinomycin—skin cancer	0.000625	0.00336	CcSEcCtD
Lapatinib—Stomatitis—Bleomycin—skin cancer	0.000623	0.00334	CcSEcCtD
Lapatinib—Palpitations—Imiquimod—skin cancer	0.000621	0.00333	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000617	0.00331	CcSEcCtD
Lapatinib—Cough—Imiquimod—skin cancer	0.000613	0.00329	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000613	0.00329	CcSEcCtD
Lapatinib—Pneumonia—Dactinomycin—skin cancer	0.000599	0.00322	CcSEcCtD
Lapatinib—Arthralgia—Imiquimod—skin cancer	0.000598	0.00321	CcSEcCtD
Lapatinib—Myalgia—Imiquimod—skin cancer	0.000598	0.00321	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000594	0.00319	CcSEcCtD
Lapatinib—Dry skin—Fluorouracil—skin cancer	0.000591	0.00317	CcSEcCtD
Lapatinib—Decreased appetite—Vemurafenib—skin cancer	0.000585	0.00314	CcSEcCtD
Lapatinib—Stomatitis—Dactinomycin—skin cancer	0.000581	0.00312	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000581	0.00312	CcSEcCtD
Lapatinib—Fatigue—Vemurafenib—skin cancer	0.00058	0.00311	CcSEcCtD
Lapatinib—Constipation—Vemurafenib—skin cancer	0.000575	0.00309	CcSEcCtD
Lapatinib—Infection—Imiquimod—skin cancer	0.00057	0.00306	CcSEcCtD
Lapatinib—Neutropenia—Temozolomide—skin cancer	0.000565	0.00303	CcSEcCtD
Lapatinib—Nervous system disorder—Imiquimod—skin cancer	0.000563	0.00302	CcSEcCtD
Lapatinib—Skin disorder—Imiquimod—skin cancer	0.000557	0.00299	CcSEcCtD
Lapatinib—Anorexia—Imiquimod—skin cancer	0.000547	0.00294	CcSEcCtD
Lapatinib—Pneumonia—Temozolomide—skin cancer	0.000542	0.00291	CcSEcCtD
Lapatinib—Infestation NOS—Temozolomide—skin cancer	0.000539	0.00289	CcSEcCtD
Lapatinib—Infestation—Temozolomide—skin cancer	0.000539	0.00289	CcSEcCtD
Lapatinib—Neuropathy peripheral—Temozolomide—skin cancer	0.000528	0.00284	CcSEcCtD
Lapatinib—Stomatitis—Temozolomide—skin cancer	0.000525	0.00282	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000523	0.00281	CcSEcCtD
Lapatinib—Insomnia—Imiquimod—skin cancer	0.000519	0.00279	CcSEcCtD
Lapatinib—Dyspnoea—Imiquimod—skin cancer	0.000511	0.00275	CcSEcCtD
Lapatinib—CYP2C8—female reproductive system—skin cancer	0.000511	0.0077	CbGeAlD
Lapatinib—Hepatobiliary disease—Temozolomide—skin cancer	0.00051	0.00274	CcSEcCtD
Lapatinib—Alopecia—Bleomycin—skin cancer	0.000507	0.00272	CcSEcCtD
Lapatinib—Dyspepsia—Imiquimod—skin cancer	0.000505	0.00271	CcSEcCtD
Lapatinib—Pneumonia—Fluorouracil—skin cancer	0.0005	0.00268	CcSEcCtD
Lapatinib—Decreased appetite—Imiquimod—skin cancer	0.000499	0.00268	CcSEcCtD
Lapatinib—Hot flush—Docetaxel—skin cancer	0.000497	0.00267	CcSEcCtD
Lapatinib—Infestation NOS—Fluorouracil—skin cancer	0.000497	0.00267	CcSEcCtD
Lapatinib—Infestation—Fluorouracil—skin cancer	0.000497	0.00267	CcSEcCtD
Lapatinib—Hypersensitivity—Vemurafenib—skin cancer	0.000496	0.00266	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000495	0.00266	CcSEcCtD
Lapatinib—Fatigue—Imiquimod—skin cancer	0.000495	0.00266	CcSEcCtD
Lapatinib—Menopausal symptoms—Docetaxel—skin cancer	0.000493	0.00265	CcSEcCtD
Lapatinib—Neuropathy peripheral—Fluorouracil—skin cancer	0.000487	0.00261	CcSEcCtD
Lapatinib—Stomatitis—Fluorouracil—skin cancer	0.000484	0.0026	CcSEcCtD
Lapatinib—Asthenia—Vemurafenib—skin cancer	0.000483	0.00259	CcSEcCtD
Lapatinib—Cardiac failure—Docetaxel—skin cancer	0.000477	0.00256	CcSEcCtD
Lapatinib—Pruritus—Vemurafenib—skin cancer	0.000476	0.00256	CcSEcCtD
Lapatinib—Connective tissue disorder—Temozolomide—skin cancer	0.000476	0.00255	CcSEcCtD
Lapatinib—Alopecia—Dactinomycin—skin cancer	0.000473	0.00254	CcSEcCtD
Lapatinib—Gastrointestinal pain—Imiquimod—skin cancer	0.000469	0.00252	CcSEcCtD
Lapatinib—Epistaxis—Fluorouracil—skin cancer	0.000468	0.00251	CcSEcCtD
Lapatinib—Pain in extremity—Docetaxel—skin cancer	0.000465	0.0025	CcSEcCtD
Lapatinib—Anaemia—Bleomycin—skin cancer	0.000462	0.00248	CcSEcCtD
Lapatinib—Diarrhoea—Vemurafenib—skin cancer	0.00046	0.00247	CcSEcCtD
Lapatinib—Abdominal pain—Imiquimod—skin cancer	0.000454	0.00243	CcSEcCtD
Lapatinib—Cardiac disorder—Temozolomide—skin cancer	0.000449	0.00241	CcSEcCtD
Lapatinib—Leukopenia—Bleomycin—skin cancer	0.000447	0.0024	CcSEcCtD
Lapatinib—Angiopathy—Temozolomide—skin cancer	0.000439	0.00236	CcSEcCtD
Lapatinib—Immune system disorder—Temozolomide—skin cancer	0.000437	0.00235	CcSEcCtD
Lapatinib—Mediastinal disorder—Temozolomide—skin cancer	0.000436	0.00234	CcSEcCtD
Lapatinib—Cough—Bleomycin—skin cancer	0.000436	0.00234	CcSEcCtD
Lapatinib—Dehydration—Docetaxel—skin cancer	0.000433	0.00232	CcSEcCtD
Lapatinib—Anaemia—Dactinomycin—skin cancer	0.00043	0.00231	CcSEcCtD
Lapatinib—Vomiting—Vemurafenib—skin cancer	0.000428	0.0023	CcSEcCtD
Lapatinib—Alopecia—Temozolomide—skin cancer	0.000428	0.0023	CcSEcCtD
Lapatinib—Dry skin—Docetaxel—skin cancer	0.000426	0.00229	CcSEcCtD
Lapatinib—Myalgia—Bleomycin—skin cancer	0.000425	0.00228	CcSEcCtD
Lapatinib—Rash—Vemurafenib—skin cancer	0.000424	0.00228	CcSEcCtD
Lapatinib—Mental disorder—Temozolomide—skin cancer	0.000424	0.00228	CcSEcCtD
Lapatinib—Dermatitis—Vemurafenib—skin cancer	0.000424	0.00227	CcSEcCtD
Lapatinib—Hypersensitivity—Imiquimod—skin cancer	0.000423	0.00227	CcSEcCtD
Lapatinib—Headache—Vemurafenib—skin cancer	0.000421	0.00226	CcSEcCtD
Lapatinib—Malnutrition—Temozolomide—skin cancer	0.000421	0.00226	CcSEcCtD
Lapatinib—Leukopenia—Dactinomycin—skin cancer	0.000417	0.00224	CcSEcCtD
Lapatinib—Asthenia—Imiquimod—skin cancer	0.000412	0.00221	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00041	0.0022	CcSEcCtD
Lapatinib—Anaphylactic shock—Bleomycin—skin cancer	0.000408	0.00219	CcSEcCtD
Lapatinib—Back pain—Temozolomide—skin cancer	0.000407	0.00219	CcSEcCtD
Lapatinib—Pruritus—Imiquimod—skin cancer	0.000406	0.00218	CcSEcCtD
Lapatinib—Infection—Bleomycin—skin cancer	0.000405	0.00217	CcSEcCtD
Lapatinib—Nausea—Vemurafenib—skin cancer	0.0004	0.00215	CcSEcCtD
Lapatinib—Myalgia—Dactinomycin—skin cancer	0.000397	0.00213	CcSEcCtD
Lapatinib—Alopecia—Fluorouracil—skin cancer	0.000394	0.00212	CcSEcCtD
Lapatinib—Diarrhoea—Imiquimod—skin cancer	0.000393	0.00211	CcSEcCtD
Lapatinib—Anaemia—Temozolomide—skin cancer	0.000389	0.00209	CcSEcCtD
Lapatinib—Anorexia—Bleomycin—skin cancer	0.000389	0.00209	CcSEcCtD
Lapatinib—Infection—Dactinomycin—skin cancer	0.000378	0.00203	CcSEcCtD
Lapatinib—Leukopenia—Temozolomide—skin cancer	0.000377	0.00202	CcSEcCtD
Lapatinib—Neutropenia—Docetaxel—skin cancer	0.000376	0.00202	CcSEcCtD
Lapatinib—Palpitations—Temozolomide—skin cancer	0.000372	0.002	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000371	0.00199	CcSEcCtD
Lapatinib—Cough—Temozolomide—skin cancer	0.000368	0.00197	CcSEcCtD
Lapatinib—Vomiting—Imiquimod—skin cancer	0.000365	0.00196	CcSEcCtD
Lapatinib—Dyspnoea—Bleomycin—skin cancer	0.000363	0.00195	CcSEcCtD
Lapatinib—Anorexia—Dactinomycin—skin cancer	0.000362	0.00195	CcSEcCtD
Lapatinib—Rash—Imiquimod—skin cancer	0.000362	0.00194	CcSEcCtD
Lapatinib—Dermatitis—Imiquimod—skin cancer	0.000361	0.00194	CcSEcCtD
Lapatinib—Pneumonia—Docetaxel—skin cancer	0.000361	0.00194	CcSEcCtD
Lapatinib—Headache—Imiquimod—skin cancer	0.000359	0.00193	CcSEcCtD
Lapatinib—Anaemia—Fluorouracil—skin cancer	0.000359	0.00193	CcSEcCtD
Lapatinib—Myalgia—Temozolomide—skin cancer	0.000359	0.00193	CcSEcCtD
Lapatinib—Arthralgia—Temozolomide—skin cancer	0.000359	0.00193	CcSEcCtD
Lapatinib—Infestation—Docetaxel—skin cancer	0.000358	0.00192	CcSEcCtD
Lapatinib—Infestation NOS—Docetaxel—skin cancer	0.000358	0.00192	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000356	0.00191	CcSEcCtD
Lapatinib—Decreased appetite—Bleomycin—skin cancer	0.000354	0.0019	CcSEcCtD
Lapatinib—Neuropathy peripheral—Docetaxel—skin cancer	0.000351	0.00189	CcSEcCtD
Lapatinib—Stomatitis—Docetaxel—skin cancer	0.000349	0.00188	CcSEcCtD
Lapatinib—Leukopenia—Fluorouracil—skin cancer	0.000347	0.00187	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000346	0.00186	CcSEcCtD
Lapatinib—CYP3A4—female reproductive system—skin cancer	0.000346	0.00521	CbGeAlD
Lapatinib—Anaphylactic shock—Temozolomide—skin cancer	0.000344	0.00185	CcSEcCtD
Lapatinib—Infection—Temozolomide—skin cancer	0.000342	0.00183	CcSEcCtD
Lapatinib—Nausea—Imiquimod—skin cancer	0.000341	0.00183	CcSEcCtD
Lapatinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000339	0.00182	CcSEcCtD
Lapatinib—Epistaxis—Docetaxel—skin cancer	0.000338	0.00182	CcSEcCtD
Lapatinib—Nervous system disorder—Temozolomide—skin cancer	0.000337	0.00181	CcSEcCtD
Lapatinib—Skin disorder—Temozolomide—skin cancer	0.000334	0.00179	CcSEcCtD
Lapatinib—Myalgia—Fluorouracil—skin cancer	0.00033	0.00177	CcSEcCtD
Lapatinib—Decreased appetite—Dactinomycin—skin cancer	0.00033	0.00177	CcSEcCtD
Lapatinib—ABCB1—epithelium—skin cancer	0.00033	0.00497	CbGeAlD
Lapatinib—Fatigue—Dactinomycin—skin cancer	0.000328	0.00176	CcSEcCtD
Lapatinib—Anorexia—Temozolomide—skin cancer	0.000328	0.00176	CcSEcCtD
Lapatinib—Anaphylactic shock—Fluorouracil—skin cancer	0.000317	0.0017	CcSEcCtD
Lapatinib—Connective tissue disorder—Docetaxel—skin cancer	0.000316	0.0017	CcSEcCtD
Lapatinib—Infection—Fluorouracil—skin cancer	0.000315	0.00169	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000313	0.00168	CcSEcCtD
Lapatinib—Insomnia—Temozolomide—skin cancer	0.000311	0.00167	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dactinomycin—skin cancer	0.000311	0.00167	CcSEcCtD
Lapatinib—Nervous system disorder—Fluorouracil—skin cancer	0.000311	0.00167	CcSEcCtD
Lapatinib—Dyspnoea—Temozolomide—skin cancer	0.000307	0.00165	CcSEcCtD
Lapatinib—Dyspepsia—Temozolomide—skin cancer	0.000303	0.00162	CcSEcCtD
Lapatinib—Anorexia—Fluorouracil—skin cancer	0.000302	0.00162	CcSEcCtD
Lapatinib—Abdominal pain—Dactinomycin—skin cancer	0.0003	0.00161	CcSEcCtD
Lapatinib—Hypersensitivity—Bleomycin—skin cancer	0.0003	0.00161	CcSEcCtD
Lapatinib—Decreased appetite—Temozolomide—skin cancer	0.000299	0.0016	CcSEcCtD
Lapatinib—Cardiac disorder—Docetaxel—skin cancer	0.000299	0.0016	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.000297	0.00159	CcSEcCtD
Lapatinib—Fatigue—Temozolomide—skin cancer	0.000296	0.00159	CcSEcCtD
Lapatinib—Constipation—Temozolomide—skin cancer	0.000294	0.00158	CcSEcCtD
Lapatinib—Asthenia—Bleomycin—skin cancer	0.000292	0.00157	CcSEcCtD
Lapatinib—Angiopathy—Docetaxel—skin cancer	0.000292	0.00157	CcSEcCtD
Lapatinib—Immune system disorder—Docetaxel—skin cancer	0.000291	0.00156	CcSEcCtD
Lapatinib—Mediastinal disorder—Docetaxel—skin cancer	0.00029	0.00156	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000289	0.00155	CcSEcCtD
Lapatinib—Pruritus—Bleomycin—skin cancer	0.000288	0.00155	CcSEcCtD
Lapatinib—Insomnia—Fluorouracil—skin cancer	0.000287	0.00154	CcSEcCtD
Lapatinib—ABCB1—mammalian vulva—skin cancer	0.000286	0.00431	CbGeAlD
Lapatinib—Alopecia—Docetaxel—skin cancer	0.000284	0.00153	CcSEcCtD
Lapatinib—Dyspnoea—Fluorouracil—skin cancer	0.000282	0.00152	CcSEcCtD
Lapatinib—Mental disorder—Docetaxel—skin cancer	0.000282	0.00151	CcSEcCtD
Lapatinib—Gastrointestinal pain—Temozolomide—skin cancer	0.000281	0.00151	CcSEcCtD
Lapatinib—Malnutrition—Docetaxel—skin cancer	0.00028	0.0015	CcSEcCtD
Lapatinib—Hypersensitivity—Dactinomycin—skin cancer	0.00028	0.0015	CcSEcCtD
Lapatinib—Dyspepsia—Fluorouracil—skin cancer	0.000279	0.0015	CcSEcCtD
Lapatinib—Decreased appetite—Fluorouracil—skin cancer	0.000275	0.00148	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000273	0.00147	CcSEcCtD
Lapatinib—Asthenia—Dactinomycin—skin cancer	0.000273	0.00146	CcSEcCtD
Lapatinib—Abdominal pain—Temozolomide—skin cancer	0.000272	0.00146	CcSEcCtD
Lapatinib—Back pain—Docetaxel—skin cancer	0.000271	0.00145	CcSEcCtD
Lapatinib—Diarrhoea—Dactinomycin—skin cancer	0.00026	0.0014	CcSEcCtD
Lapatinib—Vomiting—Bleomycin—skin cancer	0.000259	0.00139	CcSEcCtD
Lapatinib—Anaemia—Docetaxel—skin cancer	0.000259	0.00139	CcSEcCtD
Lapatinib—Rash—Bleomycin—skin cancer	0.000257	0.00138	CcSEcCtD
Lapatinib—Dermatitis—Bleomycin—skin cancer	0.000257	0.00138	CcSEcCtD
Lapatinib—ABCB1—lymphoid tissue—skin cancer	0.000254	0.00383	CbGeAlD
Lapatinib—Hypersensitivity—Temozolomide—skin cancer	0.000253	0.00136	CcSEcCtD
Lapatinib—Leukopenia—Docetaxel—skin cancer	0.000251	0.00135	CcSEcCtD
Lapatinib—Palpitations—Docetaxel—skin cancer	0.000248	0.00133	CcSEcCtD
Lapatinib—Asthenia—Temozolomide—skin cancer	0.000247	0.00132	CcSEcCtD
Lapatinib—ABCB1—female reproductive system—skin cancer	0.000245	0.00369	CbGeAlD
Lapatinib—Cough—Docetaxel—skin cancer	0.000244	0.00131	CcSEcCtD
Lapatinib—Pruritus—Temozolomide—skin cancer	0.000243	0.00131	CcSEcCtD
Lapatinib—Nausea—Bleomycin—skin cancer	0.000242	0.0013	CcSEcCtD
Lapatinib—Vomiting—Dactinomycin—skin cancer	0.000242	0.0013	CcSEcCtD
Lapatinib—Rash—Dactinomycin—skin cancer	0.00024	0.00129	CcSEcCtD
Lapatinib—Myalgia—Docetaxel—skin cancer	0.000238	0.00128	CcSEcCtD
Lapatinib—Arthralgia—Docetaxel—skin cancer	0.000238	0.00128	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000237	0.00127	CcSEcCtD
Lapatinib—Diarrhoea—Temozolomide—skin cancer	0.000235	0.00126	CcSEcCtD
Lapatinib—Hypersensitivity—Fluorouracil—skin cancer	0.000233	0.00125	CcSEcCtD
Lapatinib—Anaphylactic shock—Docetaxel—skin cancer	0.000229	0.00123	CcSEcCtD
Lapatinib—Infection—Docetaxel—skin cancer	0.000227	0.00122	CcSEcCtD
Lapatinib—Nausea—Dactinomycin—skin cancer	0.000226	0.00121	CcSEcCtD
Lapatinib—Nervous system disorder—Docetaxel—skin cancer	0.000224	0.0012	CcSEcCtD
Lapatinib—Pruritus—Fluorouracil—skin cancer	0.000224	0.0012	CcSEcCtD
Lapatinib—Skin disorder—Docetaxel—skin cancer	0.000222	0.00119	CcSEcCtD
Lapatinib—Vomiting—Temozolomide—skin cancer	0.000219	0.00117	CcSEcCtD
Lapatinib—Anorexia—Docetaxel—skin cancer	0.000218	0.00117	CcSEcCtD
Lapatinib—Rash—Temozolomide—skin cancer	0.000217	0.00116	CcSEcCtD
Lapatinib—Diarrhoea—Fluorouracil—skin cancer	0.000217	0.00116	CcSEcCtD
Lapatinib—Dermatitis—Temozolomide—skin cancer	0.000217	0.00116	CcSEcCtD
Lapatinib—Headache—Temozolomide—skin cancer	0.000215	0.00116	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000208	0.00112	CcSEcCtD
Lapatinib—Insomnia—Docetaxel—skin cancer	0.000207	0.00111	CcSEcCtD
Lapatinib—ABCB1—head—skin cancer	0.000205	0.00308	CbGeAlD
Lapatinib—Nausea—Temozolomide—skin cancer	0.000204	0.0011	CcSEcCtD
Lapatinib—Dyspnoea—Docetaxel—skin cancer	0.000204	0.00109	CcSEcCtD
Lapatinib—Vomiting—Fluorouracil—skin cancer	0.000201	0.00108	CcSEcCtD
Lapatinib—Dyspepsia—Docetaxel—skin cancer	0.000201	0.00108	CcSEcCtD
Lapatinib—Rash—Fluorouracil—skin cancer	0.0002	0.00107	CcSEcCtD
Lapatinib—Dermatitis—Fluorouracil—skin cancer	0.0002	0.00107	CcSEcCtD
Lapatinib—Decreased appetite—Docetaxel—skin cancer	0.000199	0.00107	CcSEcCtD
Lapatinib—Headache—Fluorouracil—skin cancer	0.000198	0.00107	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Docetaxel—skin cancer	0.000197	0.00106	CcSEcCtD
Lapatinib—Fatigue—Docetaxel—skin cancer	0.000197	0.00106	CcSEcCtD
Lapatinib—Constipation—Docetaxel—skin cancer	0.000196	0.00105	CcSEcCtD
Lapatinib—Nausea—Fluorouracil—skin cancer	0.000188	0.00101	CcSEcCtD
Lapatinib—Gastrointestinal pain—Docetaxel—skin cancer	0.000187	0.001	CcSEcCtD
Lapatinib—Abdominal pain—Docetaxel—skin cancer	0.000181	0.00097	CcSEcCtD
Lapatinib—Hypersensitivity—Docetaxel—skin cancer	0.000168	0.000904	CcSEcCtD
Lapatinib—Asthenia—Docetaxel—skin cancer	0.000164	0.000881	CcSEcCtD
Lapatinib—Pruritus—Docetaxel—skin cancer	0.000162	0.000868	CcSEcCtD
Lapatinib—Diarrhoea—Docetaxel—skin cancer	0.000156	0.00084	CcSEcCtD
Lapatinib—Vomiting—Docetaxel—skin cancer	0.000145	0.00078	CcSEcCtD
Lapatinib—Rash—Docetaxel—skin cancer	0.000144	0.000774	CcSEcCtD
Lapatinib—Dermatitis—Docetaxel—skin cancer	0.000144	0.000773	CcSEcCtD
Lapatinib—ABCB1—lymph node—skin cancer	0.000143	0.00216	CbGeAlD
Lapatinib—Headache—Docetaxel—skin cancer	0.000143	0.000769	CcSEcCtD
Lapatinib—Nausea—Docetaxel—skin cancer	0.000136	0.000729	CcSEcCtD
Lapatinib—EGFR—ErbB1 downstream signaling—HRAS—skin cancer	6.38e-05	0.000507	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—RASA1—skin cancer	6.37e-05	0.000507	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—PTGS2—skin cancer	6.34e-05	0.000504	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SHH—skin cancer	6.32e-05	0.000502	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—KRAS—skin cancer	6.3e-05	0.000501	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—RASA1—skin cancer	6.28e-05	0.000499	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—BRAF—skin cancer	6.22e-05	0.000495	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—NRAS—skin cancer	6.19e-05	0.000493	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—NRAS—skin cancer	6.16e-05	0.00049	CbGpPWpGaD
Lapatinib—TAP1—Immune System—KRAS—skin cancer	6.16e-05	0.00049	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—NRAS—skin cancer	6.13e-05	0.000488	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—NRAS—skin cancer	6.1e-05	0.000485	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—SMO—skin cancer	6.08e-05	0.000483	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTCH1—skin cancer	6.08e-05	0.000483	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TP53—skin cancer	6.08e-05	0.000483	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTCH2—skin cancer	6.02e-05	0.000479	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	6.02e-05	0.000478	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTCH1—skin cancer	5.99e-05	0.000476	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SMO—skin cancer	5.99e-05	0.000476	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—NRAS—skin cancer	5.99e-05	0.000476	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—KRAS—skin cancer	5.93e-05	0.000471	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—HRAS—skin cancer	5.92e-05	0.000471	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTGER4—skin cancer	5.92e-05	0.000471	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—HRAS—skin cancer	5.83e-05	0.000464	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTGER4—skin cancer	5.83e-05	0.000464	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	5.74e-05	0.000457	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—NRAS—skin cancer	5.74e-05	0.000457	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—NRAS—skin cancer	5.74e-05	0.000457	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—NRAS—skin cancer	5.69e-05	0.000453	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—KRAS—skin cancer	5.67e-05	0.000451	CbGpPWpGaD
Lapatinib—EGFR—Regulation of Actin Cytoskeleton—KRAS—skin cancer	5.67e-05	0.000451	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—IL6—skin cancer	5.67e-05	0.000451	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—NRAS—skin cancer	5.64e-05	0.000449	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—NRAS—skin cancer	5.62e-05	0.000447	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—KRAS—skin cancer	5.61e-05	0.000446	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—KRAS—skin cancer	5.58e-05	0.000444	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—IL6—skin cancer	5.58e-05	0.000444	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—IL6—skin cancer	5.56e-05	0.000442	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—HRAS—skin cancer	5.36e-05	0.000426	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—KRAS—skin cancer	5.33e-05	0.000424	CbGpPWpGaD
Lapatinib—ERBB2—Disease—ERCC2—skin cancer	5.32e-05	0.000423	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—NRAS—skin cancer	5.31e-05	0.000423	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—KRAS—skin cancer	5.31e-05	0.000422	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	5.31e-05	0.000422	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—TP53—skin cancer	5.3e-05	0.000421	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—KRAS—skin cancer	5.28e-05	0.00042	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—KRAS—skin cancer	5.25e-05	0.000418	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—SHH—skin cancer	5.25e-05	0.000417	CbGpPWpGaD
Lapatinib—ERBB4—Disease—ERCC2—skin cancer	5.24e-05	0.000417	CbGpPWpGaD
Lapatinib—TAP1—Immune System—HRAS—skin cancer	5.23e-05	0.000416	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—FOXO4—skin cancer	5.23e-05	0.000416	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—NRAS—skin cancer	5.23e-05	0.000416	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	5.18e-05	0.000412	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—KRAS—skin cancer	5.15e-05	0.00041	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—FOXO4—skin cancer	5.15e-05	0.000409	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—IL6—skin cancer	5.13e-05	0.000408	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	5.09e-05	0.000404	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—HRAS—skin cancer	5.04e-05	0.000401	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IL6—skin cancer	5.01e-05	0.000398	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—TP53—skin cancer	4.99e-05	0.000397	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TERT—skin cancer	4.99e-05	0.000396	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PTCH1—skin cancer	4.98e-05	0.000396	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—SMO—skin cancer	4.98e-05	0.000396	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	4.94e-05	0.000393	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—KRAS—skin cancer	4.94e-05	0.000393	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—KRAS—skin cancer	4.94e-05	0.000393	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	4.92e-05	0.000391	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TERT—skin cancer	4.91e-05	0.000391	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.9e-05	0.00039	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—KRAS—skin cancer	4.9e-05	0.000389	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—KRAS—skin cancer	4.86e-05	0.000386	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PTGER4—skin cancer	4.84e-05	0.000385	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—KRAS—skin cancer	4.83e-05	0.000384	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—IL6—skin cancer	4.82e-05	0.000383	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—HRAS—skin cancer	4.82e-05	0.000383	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—HRAS—skin cancer	4.75e-05	0.000377	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.65e-05	0.00037	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—NRAS—skin cancer	4.62e-05	0.000367	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—IL6—skin cancer	4.62e-05	0.000367	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TP53—skin cancer	4.58e-05	0.000364	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—KRAS—skin cancer	4.57e-05	0.000364	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GLI2—skin cancer	4.56e-05	0.000363	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—NRAS—skin cancer	4.55e-05	0.000361	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—CDK4—skin cancer	4.54e-05	0.000361	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—IL6—skin cancer	4.54e-05	0.000361	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—HRAS—skin cancer	4.53e-05	0.00036	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PLIN2—skin cancer	4.53e-05	0.00036	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	4.51e-05	0.000359	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—HRAS—skin cancer	4.51e-05	0.000359	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—KRAS—skin cancer	4.5e-05	0.000358	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—HRAS—skin cancer	4.49e-05	0.000357	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—HRAS—skin cancer	4.47e-05	0.000355	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—NRAS—skin cancer	4.43e-05	0.000352	CbGpPWpGaD
Lapatinib—EGFR—Disease—SHH—skin cancer	4.43e-05	0.000352	CbGpPWpGaD
Lapatinib—EGFR—Disease—ENO2—skin cancer	4.43e-05	0.000352	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	4.4e-05	0.00035	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	4.38e-05	0.000348	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—NRAS—skin cancer	4.37e-05	0.000347	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MC1R—skin cancer	4.35e-05	0.000346	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—IL6—skin cancer	4.34e-05	0.000345	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—IL6—skin cancer	4.32e-05	0.000343	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—IL6—skin cancer	4.3e-05	0.000341	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GLI1—skin cancer	4.29e-05	0.000341	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—IL6—skin cancer	4.27e-05	0.00034	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	4.23e-05	0.000336	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—HRAS—skin cancer	4.2e-05	0.000334	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	4.2e-05	0.000334	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—HRAS—skin cancer	4.2e-05	0.000334	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—HRAS—skin cancer	4.16e-05	0.000331	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.13e-05	0.000329	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—HRAS—skin cancer	4.13e-05	0.000328	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—HRAS—skin cancer	4.11e-05	0.000327	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SUFU—skin cancer	4.07e-05	0.000323	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	4.02e-05	0.00032	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—IL6—skin cancer	4.02e-05	0.00032	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—IL6—skin cancer	4.02e-05	0.00032	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—IL6—skin cancer	3.99e-05	0.000317	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—KRAS—skin cancer	3.97e-05	0.000316	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—HRAS—skin cancer	3.97e-05	0.000316	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—IL6—skin cancer	3.95e-05	0.000314	CbGpPWpGaD
Lapatinib—ERBB2—Disease—BRAF—skin cancer	3.95e-05	0.000314	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—IL6—skin cancer	3.93e-05	0.000313	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PLIN2—skin cancer	3.92e-05	0.000312	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—KRAS—skin cancer	3.91e-05	0.000311	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—NRAS—skin cancer	3.91e-05	0.000311	CbGpPWpGaD
Lapatinib—EGFR—Immune System—FOXO4—skin cancer	3.91e-05	0.000311	CbGpPWpGaD
Lapatinib—ERBB4—Disease—BRAF—skin cancer	3.89e-05	0.000309	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—HRAS—skin cancer	3.89e-05	0.000309	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—HRAS—skin cancer	3.82e-05	0.000304	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—KRAS—skin cancer	3.81e-05	0.000303	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—KRAS—skin cancer	3.76e-05	0.000299	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	3.72e-05	0.000296	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—IL6—skin cancer	3.66e-05	0.000291	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CSPG4—skin cancer	3.65e-05	0.00029	CbGpPWpGaD
Lapatinib—EGFR—Disease—FOXO4—skin cancer	3.61e-05	0.000287	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	3.6e-05	0.000286	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	3.56e-05	0.000283	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—NRAS—skin cancer	3.54e-05	0.000282	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	3.51e-05	0.000279	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PLIN2—skin cancer	3.5e-05	0.000278	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TERT—skin cancer	3.49e-05	0.000278	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	3.44e-05	0.000274	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TERT—skin cancer	3.44e-05	0.000273	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PLIN2—skin cancer	3.42e-05	0.000272	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—HRAS—skin cancer	3.38e-05	0.000268	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—KRAS—skin cancer	3.37e-05	0.000268	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—HRAS—skin cancer	3.33e-05	0.000264	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—HRAS—skin cancer	3.24e-05	0.000258	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—IL6—skin cancer	3.23e-05	0.000257	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—HRAS—skin cancer	3.19e-05	0.000254	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PTGS2—skin cancer	3.19e-05	0.000254	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—IL6—skin cancer	3.18e-05	0.000253	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CSPG4—skin cancer	3.16e-05	0.000251	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTGS2—skin cancer	3.14e-05	0.00025	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SHH—skin cancer	3.1e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RASA1—skin cancer	3.08e-05	0.000245	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—KRAS—skin cancer	3.05e-05	0.000242	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SMO—skin cancer	2.94e-05	0.000234	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTCH1—skin cancer	2.94e-05	0.000234	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—HRAS—skin cancer	2.86e-05	0.000228	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTGER4—skin cancer	2.86e-05	0.000228	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CSPG4—skin cancer	2.82e-05	0.000224	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—BRAF—skin cancer	2.77e-05	0.00022	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CSPG4—skin cancer	2.75e-05	0.000219	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—IL6—skin cancer	2.74e-05	0.000218	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—BRAF—skin cancer	2.72e-05	0.000217	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—NRAS—skin cancer	2.69e-05	0.000214	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—NRAS—skin cancer	2.65e-05	0.000211	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—HRAS—skin cancer	2.59e-05	0.000206	CbGpPWpGaD
Lapatinib—EGFR—Disease—ERCC2—skin cancer	2.57e-05	0.000204	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FOXO4—skin cancer	2.53e-05	0.000201	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—NRAS—skin cancer	2.53e-05	0.000201	CbGpPWpGaD
Lapatinib—ERBB2—Disease—NRAS—skin cancer	2.48e-05	0.000197	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ENO2—skin cancer	2.48e-05	0.000197	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—IL6—skin cancer	2.48e-05	0.000197	CbGpPWpGaD
Lapatinib—ERBB4—Disease—NRAS—skin cancer	2.44e-05	0.000194	CbGpPWpGaD
Lapatinib—EGFR—Disease—TERT—skin cancer	2.41e-05	0.000192	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.35e-05	0.000187	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KRAS—skin cancer	2.31e-05	0.000184	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KRAS—skin cancer	2.28e-05	0.000181	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NRAS—skin cancer	2.23e-05	0.000177	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—KRAS—skin cancer	2.17e-05	0.000173	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ENO2—skin cancer	2.15e-05	0.000171	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NRAS—skin cancer	2.14e-05	0.00017	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KRAS—skin cancer	2.14e-05	0.00017	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLIN2—skin cancer	2.1e-05	0.000167	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KRAS—skin cancer	2.1e-05	0.000167	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.09e-05	0.000166	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HRAS—skin cancer	1.97e-05	0.000156	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HRAS—skin cancer	1.94e-05	0.000154	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KRAS—skin cancer	1.92e-05	0.000153	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ENO2—skin cancer	1.92e-05	0.000152	CbGpPWpGaD
Lapatinib—EGFR—Disease—BRAF—skin cancer	1.91e-05	0.000152	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—skin cancer	1.88e-05	0.00015	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ENO2—skin cancer	1.87e-05	0.000149	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—skin cancer	1.85e-05	0.000147	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—HRAS—skin cancer	1.85e-05	0.000147	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KRAS—skin cancer	1.84e-05	0.000147	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HRAS—skin cancer	1.82e-05	0.000144	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HRAS—skin cancer	1.79e-05	0.000142	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—skin cancer	1.77e-05	0.000141	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRAS—skin cancer	1.74e-05	0.000138	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—skin cancer	1.74e-05	0.000138	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRAS—skin cancer	1.71e-05	0.000136	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—skin cancer	1.71e-05	0.000136	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CSPG4—skin cancer	1.7e-05	0.000135	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TERT—skin cancer	1.69e-05	0.000134	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.68e-05	0.000134	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HRAS—skin cancer	1.63e-05	0.00013	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HRAS—skin cancer	1.57e-05	0.000125	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—skin cancer	1.56e-05	0.000124	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—skin cancer	1.54e-05	0.000123	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.5e-05	0.000119	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—skin cancer	1.5e-05	0.000119	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—skin cancer	1.47e-05	0.000117	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ERCC2—skin cancer	1.44e-05	0.000115	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—NRAS—skin cancer	1.42e-05	0.000113	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—BRAF—skin cancer	1.34e-05	0.000106	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—skin cancer	1.33e-05	0.000106	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—skin cancer	1.31e-05	0.000104	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRAS—skin cancer	1.3e-05	0.000103	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—skin cancer	1.27e-05	0.000101	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—skin cancer	1.25e-05	9.96e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ERCC2—skin cancer	1.25e-05	9.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—skin cancer	1.22e-05	9.73e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—skin cancer	1.22e-05	9.68e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRAS—skin cancer	1.2e-05	9.54e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—skin cancer	1.2e-05	9.53e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ENO2—skin cancer	1.15e-05	9.17e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—skin cancer	1.12e-05	8.89e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ERCC2—skin cancer	1.11e-05	8.86e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ERCC2—skin cancer	1.09e-05	8.64e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—skin cancer	1.04e-05	8.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—skin cancer	1.03e-05	8.21e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—skin cancer	9.96e-06	7.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—skin cancer	9.51e-06	7.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—skin cancer	9.1e-06	7.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—skin cancer	8.78e-06	6.98e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—skin cancer	8.64e-06	6.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRAS—skin cancer	8.4e-06	6.68e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—skin cancer	8.4e-06	6.68e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—skin cancer	7.48e-06	5.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—skin cancer	7.23e-06	5.75e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ERCC2—skin cancer	6.7e-06	5.33e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—skin cancer	6.68e-06	5.31e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—skin cancer	6.52e-06	5.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—skin cancer	6.43e-06	5.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—skin cancer	6.15e-06	4.89e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—skin cancer	5.88e-06	4.68e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—skin cancer	4.02e-06	3.19e-05	CbGpPWpGaD
